These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22179954)

  • 21. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.
    Sehouli J; Alvarez AM; Manouchehrpour S; Ghatage P; Szczylik C; Zimmermann A; Bauknecht T; Look KY; Oskay-Öezcelik G
    Gynecol Oncol; 2012 Feb; 124(2):205-9. PubMed ID: 22044606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
    Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
    J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
    J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
    Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
    Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
    Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Taylor L; Ashland J; Ye Z; Monberg MJ; Obasaju CK
    Clin Lung Cancer; 2005 Jul; 7(1):40-6. PubMed ID: 16098243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed for primary central nervous system lymphoma in the elderly.
    Han S; Wang M; Liu B; Yu J
    Clin Transl Oncol; 2016 Feb; 18(2):138-43. PubMed ID: 26169215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.
    Zhang JP; Lee EQ; Nayak L; Doherty L; Kesari S; Muzikansky A; Norden AD; Chen H; Wen PY; Drappatz J
    J Neurooncol; 2013 Oct; 115(1):71-7. PubMed ID: 23828279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
    Miller DS; Blessing JA; Krasner CN; Mannel RS; Hanjani P; Pearl ML; Waggoner SE; Boardman CH
    J Clin Oncol; 2009 Jun; 27(16):2686-91. PubMed ID: 19332726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
    Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
    Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience.
    Xie H; Dahiya S; Murphy ES; Chao ST; Suh JH; Stevens GH; Peereboom DM; Ahluwalia MS
    Anticancer Res; 2013 Aug; 33(8):3251-8. PubMed ID: 23898087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a role for radiotherapy in the primary management of primary central nervous system lymphoma? A single-centre case series.
    Muirhead R; Murray EC; Bell SL; Stewart W; James A
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):400-5. PubMed ID: 23688624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.